+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Shigella Infections (Shigellosis) - Pipeline Review, H1 2015

  • ID: 3196292
  • Report
  • March 2015
  • 47 pages
  • Global Markets Direct
1 of 5
Shigella Infections (Shigellosis) - Pipeline Review, H1 2015

Summary

This, ‘Shigella Infections (Shigellosis) - Pipeline Review, H1 2015’, provides an overview of the Shigella Infections (Shigellosis)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Shigella Infections (Shigellosis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Shigella Infections (Shigellosis) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope:

- The report provides a snapshot of the global therapeutic landscape of Shigella Infections (Shigellosis)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Shigella Infections (Shigellosis) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Shigella Infections (Shigellosis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Shigella Infections (Shigellosis) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Purchase:

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Shigella Infections (Shigellosis)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Shigella Infections (Shigellosis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope:
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5
List of Tables:

List of Figures:

Introduction

REPORT COVERAGE

Shigella Infections (Shigellosis) Overview

Therapeutics Development

Pipeline Products for Shigella Infections (Shigellosis) - Overview

Pipeline Products for Shigella Infections (Shigellosis) - Comparative Analysis

Shigella Infections (Shigellosis) - Therapeutics under Development by Companies

Shigella Infections (Shigellosis) - Therapeutics under Investigation by Universities/Institutes

Shigella Infections (Shigellosis) - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Shigella Infections (Shigellosis) - Products under Development by Companies

Shigella Infections (Shigellosis) - Products under Investigation by Universities/Institutes

Shigella Infections (Shigellosis) - Companies Involved in Therapeutics Development

Anacor Pharmaceuticals, Inc.

GlaxoSmithKline plc

GlycoVaxyn AG

Shigella Infections (Shigellosis) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

1790GAHB Vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GVXNSD-133 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

INX-201 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

KKL-35 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

shigella vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

shigella vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Shigella Vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

shigella vaccine 1 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

shigellosis [Shigella flexneri 2a] (whole cell) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Shigetec - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule for Shigellosis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Inhibit Rns and VirF for Bacterial Infections - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Shigella Infections (Shigellosis) - Recent Pipeline Updates

Shigella Infections (Shigellosis) - Dormant Projects

Shigella Infections (Shigellosis) - Discontinued Products

Shigella Infections (Shigellosis) - Product Development Milestones

Featured News & Press Releases

Jul 29, 2013: GlycoVaxyn Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine

Feb 20, 2013: NIH-Funded Researchers Begin Trial of Shigella Vaccine Candidates

Jan 27, 2012: IVI Granted Two U.S. Patents On Dysentery Vaccine Inventions

Oct 08, 2010: GlycoVaxyn Phase I Clinical Study Shows Positive Data With Shigella Dysenteriae Vaccine Candidate Against Severe Diarrheal Disease

Feb 23, 2010: GlycoVaxyn Initiates Phase I Clinical Study with Bioconjugate Vaccine

Feb 15, 2007: IVI Scientists Develop New Laboratory Animal Model For Shigella

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Shigella Infections (Shigellosis), H1 2015

Number of Products under Development for Shigella Infections (Shigellosis) - Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Number of Products under Investigation by Universities/Institutes, H1 2015

Comparative Analysis by Clinical Stage Development, H1 2015

Comparative Analysis by Early Stage Development, H1 2015

Products under Development by Companies, H1 2015

Products under Investigation by Universities/Institutes, H1 2015

Shigella Infections (Shigellosis) - Pipeline by Anacor Pharmaceuticals, Inc., H1 2015

Shigella Infections (Shigellosis) - Pipeline by GlaxoSmithKline plc, H1 2015

Shigella Infections (Shigellosis) - Pipeline by GlycoVaxyn AG, H1 2015

Assessment by Monotherapy Products, H1 2015

Number of Products by Stage and Target, H1 2015

Number of Products by Stage and Route of Administration, H1 2015

Number of Products by Stage and Molecule Type, H1 2015

Shigella Infections (Shigellosis) Therapeutics - Recent Pipeline Updates, H1 2015

Shigella Infections (Shigellosis) - Dormant Projects, H1 2015

Shigella Infections (Shigellosis) - Discontinued Products, H1 2015

List of Figures:

Number of Products under Development for Shigella Infections (Shigellosis), H1 2015

Number of Products under Development for Shigella Infections (Shigellosis) - Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Number of Products under Investigation by Universities/Institutes, H1 2015

Comparative Analysis by Clinical Stage Development, H1 2015

Comparative Analysis by Early Stage Products, H1 2015

Assessment by Monotherapy Products, H1 2015

Number of Products by Top 10 Targets, H1 2015

Number of Products by Stage and Top 10 Targets, H1 2015

Number of Products by Top 10 Routes of Administration, H1 2015

Number of Products by Stage and Top 10 Routes of Administration, H1 2015

Number of Products by Top 10 Molecule Types, H1 2015

Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
4 of 5
- Anacor Pharmaceuticals, Inc.
- GlaxoSmithKline plc
- GlycoVaxyn AG
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll